Walgreen, the USA's largest drugstore chain, has signed a definitive agreement to acquire McKesson Corp's specialty pharmacy, which is a business within the latter's specialty division. Terms of the deal were not disclosed. The acquisition will further strengthen Walgreen's position as the fourth-largest specialty pharmacy in the country. Subject to satisfaction of customary conditions, the parties expect the transaction to close within 60 days.
"The acquisition of McKesson's specialty pharmacy operations offers the opportunity to grow our own specialty pharmacy business with preferred payer agreements," said Stanley Blaylock, president of Walgreen's Health Services. "This transaction will broaden access for patients and clients in the fast-growing oncology area and other specialty areas including multiple sclerosis, rheumatoid arthritis and reproductive health services," he added.
The purchase includes the McKesson specialty pharmacy in Pittsburgh, Pennsylvania, and IVPCARE based in Frisco, Texas, with operations in Torrence, California, Wilmington, Massachusetts and St Louis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze